ArticlePloS one2014
Stabilization and augmentation of circulating AIM in mice by synthesized IgM-Fc.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 31 citations in OpenAlex.
- A kidney-protective mechanism via cellular oxidative stress reduction induced by CD5L protein.Cell death discovery · 2026Article
- Apoptosis Inhibitor of Macrophage (AIM) Modulates Calcium Oxalate-Induced Ureteral Fibrosis in AIM-Felinized Mice.International journal of molecular sciences · 2025Article
- Release of apoptosis inhibitor of macrophage (AIM) from pentameric IgM in serum predicts prognosis after hemodialysis initiation.Communications medicine · 2025Article
- Endogenous CD5L controls the metabolic and inflammatory state of human macrophages.Frontiers in immunology · 2025Article
- Cryo-EM reveals structural basis for human AIM/CD5L recognition of polymeric immunoglobulin M.Nature communications · 2024Article
- The effects of apoptosis inhibitor of macrophage in kidney diseases.European journal of medical research · 2024Review
- The comprehensive role of apoptosis inhibitor of macrophage (AIM) in pathological conditions.Clinical and experimental immunology · 2023Review
- CD5L Secreted by Macrophage on Atherosclerosis Progression Based on Lipid Metabolism Induced Inflammatory Damage.Archivum immunologiae et therapiae experimentalis · 2022Article
- Multiple sclerosis and obesity: The role of adipokines.Frontiers in immunology · 2022Review
- Profiling the serum proteome duringFrontiers in immunology · 2022Article
- 3D Structures of IgA, IgM, and Components.International journal of molecular sciences · 2021Review
- Proteomic Analysis of the Alterations in Follicular Fluid Proteins During Oocyte Maturation in Humans.Frontiers in endocrinology · 2021Article
- Immunoglobulin M: An Ancient Antiviral Weapon - Rediscovered.Frontiers in immunology · 2020Review
- A scavenging system against internal pathogens promoted by the circulating protein apoptosis inhibitor of macrophage (AIM).Seminars in immunopathology · 2018Review
- The IgM pentamer is an asymmetric pentagon with an open groove that binds the AIM protein.Science advances · 2018Article
- AIM associated with the IgM pentamer: attackers on stand-by at aircraft carrier.Cellular & molecular immunology · 2018Review
- Association of apoptosis inhibitor of macrophage (AIM) expression with urinary protein and kidney dysfunction.Clinical and experimental nephrology · 2017Article
- A proteolytic modification of AIM promotes its renal excretion.Scientific reports · 2016Article
- Impact of feline AIM on the susceptibility of cats to renal disease.Scientific reports · 2016Article
- Apoptosis inhibitor of macrophage (AIM) reduces cell number in canine histiocytic sarcoma cell lines.The Journal of veterinary medical science · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Owing to rapid and drastic changes in lifestyle and eating habits in modern society, obesity and obesity-associated diseases are among the most important public health problems. Hence, the development of therapeutic approaches to regulate obesity is strongly desired. In view of previous work showing that apoptosis inhibitor of macrophage (AIM) blocks lipid storage in adipocytes, thereby preventing obesity caused by a high-fat diet, we here explored a strategy to augment circulating AIM levels. We synthesized the Fc portion of the soluble human immunoglobulin (Ig)M heavy chain and found that it formed a pentamer containing IgJ as natural IgM does, and effectively associated with AIM in vitro. When we injected the synthesized Fc intravenously into mice lacking circulating IgM, it associated with endogenous mouse AIM, protecting AIM from renal excretion and preserving the circulating AIM levels. As the synthesized Fc lacked the antigen-recognizing variable region, it provoked no undesired immune response. In addition, a challenge with the Fc-human AIM complex in wild-type mice, which exhibited normal levels of circulating IgM and AIM, successfully maintained the levels of the human AIM in mouse blood. We also observed that the human AIM was effectively incorporated into adipocytes in visceral fat tissue, suggesting its functionality against obesity. Thus, our findings reveal potent strategies to safely increase AIM levels, which could form the basis for developing novel therapies for obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.